title: Outcome of cardiac transplant recipients with a positive donor-specific crossmatch--preliminary results with plasmapheresis.
abstract: To assess the influence of a positive T or B cell IgG crossmatch on the development of rejection and mortality following cardiac transplantation, we reviewed all cardiac transplants performed in Utah between March 1985 and October 1990. Of the 328 cardiac allograft recipients, 11 (3.4%) had an IgG positive crossmatch. Actuarial survival at 24 months in the positive crossmatch group was 57.3% +/- 0.02 while that of the controls was 86.1% +/- 2.1 (P < 0.05). Allograft rejection occurred earlier in recipients with a positive crossmatch (10.0 +/- 5.8 days versus 34.0 +/- 2.3 days, P < 0.001). The first allograft rejection episode in patients with a positive crossmatch was characterized by immunoglobulin and complement deposition in small blood vessels and interstitial edema and endothelial cell activation in the absence of a lymphocytic infiltrate. Furthermore, the allograft rejection in the positive crossmatch group was accompanied by hemodynamic compromise in a large proportion of the patients (73%). In addition to augmentation of immunosuppression, plasma exchange therapy was performed within the first week following transplantation in 8 of the 11 positive crossmatch patients. Survival in the patients treated with plasma exchange (75%) appears to be better than in those not receiving plasma exchange (33%) within one week of transplantation. While immunosuppressive therapy aimed at the humoral arm of the immune system and plasma exchange therapy may improve survival in recipients with a positive donor-specific crossmatch, survival is worse in patients with a positive crossmatch than in patients with a negative crossmatch. Thus, it would appear prudent to prospectively crossmatch cardiac transplant candidates with a greater risk of developing a positive crossmatch, such as those potential recipients with an elevated level of panel-reactive antibodies.
authors.affiliation: Division of Cardiology, University of Utah Medical Center, LDS Hospital, Salt Lake City.
authors.forename: R M
authors.initials: RM
authors.lastname: Ratkovec
authors.forename: E H
authors.initials: EH
authors.lastname: Hammond
authors.forename: J B
authors.initials: JB
authors.lastname: O'Connell
authors.forename: M R
authors.initials: MR
authors.lastname: Bristow
authors.forename: C W
authors.initials: CW
authors.lastname: DeWitt
authors.forename: W E
authors.initials: WE
authors.lastname: Richenbacher
authors.forename: R C
authors.initials: RC
authors.lastname: Millar
authors.forename: D G
authors.initials: DG
authors.lastname: Renlund
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D010956:Plasmapheresis; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors
chemical_list: D007074:Immunoglobulin G